Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen Paying $1.9bn For Five Prime And Its Gastric Cancer Antibody

Executive Summary

Five Prime’s Phase III-ready bemarituzumab could offer significant revenue for Amgen, particularly in Asia, but analysts ask if the buyout is a precursor to greater deal making by Amgen.

You may also be interested in...



Five Prime Founder Rusty Williams Returns With Walking Fish Therapeutics

Named after a remarkable self-regenerating salamander, the new San Francisco biotech aims to unlock the potential of B-cells to be “in vivo protein factories”.

Amgen CEO Shines Light On Opportunities For Accelerated Drug Pathways

Amgen CEO Robert Bradway spotlights opportunities to up the tempo of drug discovery and development, drawing from the success of COVID-19 vaccines, and touches on the company's breakthrough treatment Lumakras and efforts in gastric cancer.

Amgen After ASCO: Questions Remain On Lumakras, Bemarituzumab

Remaining questions after ASCO include whether Lumakras (sotorasib) might work in first-line NSCLC with certain co-mutations and if ocular toxicities will hamper bemarituzumab in gastric cancer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143939

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel